⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15167302 | 1.00 | — | — | |
| SCHEMBL2014129 | 0.80 | ALDH1A1 (0.30) | — | |
| SCHEMBL14739959 | 0.78 | — | — | |
| SCHEMBL17748990 | 0.78 | — | — | |
| SCHEMBL290166 | 0.78 | — | — | |
| SCHEMBL17505971 | 0.76 | KDM4E (0.31) | — | |
| SCHEMBL254956 | 0.76 | — | — | |
| SCHEMBL8852659 | 0.75 | LPAR2 (0.30) | — | |
| SCHEMBL8852654 | 0.75 | LPAR2 (0.30) | — | |
| SCHEMBL15638549 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552796-B2 | EED inhibitor, and preparation method therefor and use thereof | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| EP-4056570-B1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-01-07 | — | — | EP | disclosed |
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| CN-118652256-A | EED inhibitor and preparation method and application thereof | 上海科技大学 | 2024-09-17 | — | — | CN | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| CN-114929707-B | EED inhibitor and preparation method and application thereof | 上海科技大学 | 2024-04-09 | — | — | CN | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-4143179-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-2770987-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013175053-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORPORATION (FI) | 2013-11-28 | — | — | WO | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2013063214-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-8324226-B2 | Therapeutic oxy-phenyl-aryl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| EP-2227460-B1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| EP-2227460-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009053694-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |